Safety of intravitreal chemotherapy in the management of retinoblastoma: A systematic review of the literature.

Intravitreal chemotherapy is used as a salvage therapy for retinoblastoma with persistent or recurrent vitreous seeding after primary treatment. To assess the safety of this technique, we conducted a systematic review of all studies reporting ocular toxicity data. Forty-eight trials involving 2751 eyes were included. The most common complications were cataract, retinal toxicity, and vitreous hemorrhage. However, severe and permanent adverse events were limited, while the risk of extraocular dissemination, a significant concern, was practically eliminated through preventive techniques. Globe salvage rates ranged from 29 % to 100 %. In conclusion, intravitreal chemotherapy seems to improve prognosis of eyes with advanced disease, with an acceptable safety profile. Nevertheless, most relevant studies are retrospective, and no randomized trials have been performed. Recognizing the challenges regarding the conduct of randomized studies for such a rare pediatric cancer, we believe that multicenter trials through international collaborations can significantly enhance the available information. Copyright © 2024 Elsevier B.V. All rights reserved.

Citation

Georgios Lavasidis, Mara Strongylis, Argyrios Tzamalis, Ioannis Tsinopoulos, Evangelia E Ntzani. Safety of intravitreal chemotherapy in the management of retinoblastoma: A systematic review of the literature. Critical reviews in oncology/hematology. 2024 Aug;200:104423

Mesh Tags

Substances

PMID: 38897313

search → result